Oncocyte Corp. Files 8-K with Corporate Updates
Ticker: IMDX · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1642380
Sentiment: neutral
Topics: corporate-governance, filing, regulatory-disclosure
TL;DR
Oncocyte Corp. filed an 8-K on 6/13/25 for corporate updates and financial filings.
AI Summary
On June 13, 2025, Oncocyte Corp. filed an 8-K report detailing amendments to its Articles of Incorporation and Bylaws, along with Regulation FD disclosures and financial statements. The company, previously known as Insight Molecular Diagnostics Inc., is incorporated in California and has its principal executive offices in Irvine, CA.
Why It Matters
This filing indicates significant corporate governance changes and regulatory disclosures for Oncocyte Corp., which could impact its operational structure and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- Oncocyte Corp (company) — Registrant
- Insight Molecular Diagnostics Inc. (company) — Former name of Registrant
- June 13, 2025 (date) — Date of earliest event reported
- California (jurisdiction) — State of incorporation
- Irvine, CA (location) — Business address
FAQ
What specific amendments were made to Oncocyte Corp.'s Articles of Incorporation or Bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary information.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
Regulation FD disclosures ensure that material non-public information is broadly disseminated to the public, preventing selective disclosure to analysts or institutional investors.
When was Oncocyte Corp. previously known as Insight Molecular Diagnostics Inc.?
The filing does not specify the exact date range for the former name 'Insight Molecular Diagnostics Inc.', only that Oncocyte Corp. is the current registrant.
What is the primary business of Oncocyte Corp. based on its SIC code?
Oncocyte Corp.'s Standard Industrial Classification (SIC) code is 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Where are Oncocyte Corp.'s principal executive offices located?
Oncocyte Corp.'s principal executive offices are located at 15 Cushing, Irvine, CA 92618.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Oncocyte Corp (IMDX).